Whence and whither the fixed-dose combination?

1. Turner RC , Cull CA , Frighi V , Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–12.

2. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000;7:625–31.

3. Hermann LS , Schersten B , Bitzen PO et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100–09.

4. Garber AJ , Larsen J , Schneider SH et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obesity Metab 2002;4:201–08.

5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Targets for glycemic control. Can J Diabetes 2003;27(suppl 2):S37–S42. (http://www.diabetes.ca/cpg2003/downloads/pharmacologic.pdf last accessed March 2005).

6. Donnan PT , MacDonald TM , Morris AD for the DARTS/MEMO collaboration. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabetic Med 2002;19:279–84.

7. Emslie-Smith A , Dowall J , Morris A. The problem of polypharmacy in type 2 diabetes. Br J Diabetes Vasc Dis 2003;3:54–6.

8. Melikian C , White TJ , Vanderplas A et al. Adherence to oral antidiabetic therapy in a managed care organisation: a comparison of monotherapy, combination, and fixed-dose combination therapy. Clin Therapeutics 2002;24:460–7.

9. Garber AJ , Donovan DS , Dandona P et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598–604.

10. Bailey CJ , Day C. Avandamet: combined metformin-rosiglitazone treatment against insulin resistance in type 2 diabetes. Int J Clin Pract 2004;58:867–76.

11. Bajaj M , DeFronzo RA. Combination therapy in type 2 diabetes. In International Textbook of Diabetes Mellitus, 3rd edn. DeFronzo RA , Ferrannini E , Keen H , Zimmet P eds. Wiley: Chichester 2004, 915–50.

12. McCluskey D , Touger MS , Melis R , Schleusener DS. Result of a randomized double-blind, placebo controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin Therapeutics 2004;26:1783–90.

13. Rendell MS , Glazer NB , Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 2003;17:211–17.

14. Skolnik NS , Beck JD , Clark M. Combination antihypertensive drugs: recommendations for use. Am Family Physician 2000;61:3049–56.

15. Weir MR. When antihypertensive monotherapy fails: fixed-dose combination therapy. South Med J 2000;93:548–56.

16. Bailey CJ. New drugs for the treatment of diabetes mellitus. In International Textbook of Diabetes Mellitus, 3rd edn. DeFronzo RA , Ferrannini E , Keen H , Zimmet P eds. Wiley: Chichester 2004, 951–79.

17. Wald NJ , Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003;326:1419–23.

18. Gaede P , Vedel P , Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.